Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Open Access
- 1 November 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (9) , 1135-1142
- https://doi.org/10.1086/508174
Abstract
Background. Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and otherKeywords
This publication has 18 references indexed in Scilit:
- Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003Journal of Clinical Microbiology, 2005
- Vaccination strategies for an influenza pandemic.The Journal of Infectious Diseases, 2005
- Continuing Evolution of H9N2 Influenza Viruses in Southeastern ChinaJournal of Virology, 2004
- Confronting the avian influenza threat: vaccine development for a potential pandemicThe Lancet Infectious Diseases, 2004
- Avian Influenza A (H5N1) in 10 Patients in VietnamNew England Journal of Medicine, 2004
- Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the NetherlandsThe Lancet, 2004
- Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialThe Lancet, 2003
- H9N2 Influenza A Viruses from Poultry in Asia Have Human Virus-like Receptor SpecificityVirology, 2001
- Human infection with influenza H9N2The Lancet, 1999
- Summary of Clinical Trials of Inactivated Influenza Vaccine--1978Clinical Infectious Diseases, 1983